Your Daily Pharma Scoop: Achaogen Update, Catabasis' Positive Results, Bristol-Myers Squibb/Nektar Collaboration

Achaogen remains attractive ahead of catalyst. Catabasis announces positive results from the extension portion of edasalonexent phase 2 study. Bristol-Myers Squibb and Nektar ink global development and commercialization agreement. Today we will focus on ...